Targeted Graphene Oxide Networks: Cytotoxicity and Synergy with Anticancer Agents

Area of Science:

• Biomedical Engineering
• Materials Science
• Oncology

Background:

• Endocytosis is a key mechanism for cancer cell survival and proliferation.
• Developing novel agents to inhibit endocytosis is a promising anticancer strategy.
• Graphene oxide (GO) possesses unique properties suitable for biomedical applications.

Purpose of the Study:

• To synthesize and evaluate modified graphene oxide (GO) sheets as novel anticancer agents.
• To investigate the mechanism of GO-mediated inhibition of cancer cell endocytosis.
• To assess the synergistic effects of modified GO with chemotherapy drugs.

Main Methods:

• Synthesis of folate-PEGylated GO (GO-PEGFA) and Arg-Gly-Asp-PEGylated GO (GO-PEGRGD).
• Live cell confocal microscopy to track GO internalization and cell membrane association.
• In vitro cell viability assays to determine cytotoxicity of GO agents and drug combinations.

Main Results:

• GO-PEGFA was internalized by tumor cells, while GO-PEGRGD associated with the cell membrane.
• GO-PEGFA and GO-PEGRGD reduced tumor cell viability by 35% compared to methotrexate (50% reduction).
• Combination therapy with modified GO and methotrexate or doxorubicin achieved an 80% reduction in cell viability, demonstrating significant synergy.

Conclusions:

• Modified GO sheets effectively inhibit cancer cell endocytosis and reduce tumor growth.
• The synergistic effect of GO combined with chemotherapy drugs offers a potent strategy for cancer treatment.
• This approach presents a novel and effective method for limiting tumor cell proliferation.